Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8485512 | Vaccine | 2018 | 6 Pages |
Abstract
These data continue to support the generally favorable safety profile of JE-VC. Reporting rates of adverse events were similar to those of the previous analysis. Although reporting rates of adverse events in children could not be calculated, there were low numbers of reported events in this age group. Post-licensure adverse event surveillance for this relatively new vaccine continues to be important to monitor adverse event reporting rates and identify possible rare serious events.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
William L. Walker, Susan L. Hills, Elaine R. Miller, Marc Fischer, Ingrid B. Rabe,